Format
Items per page
Sort by

Send to:

Choose Destination

Links from PubMed

Items: 1 to 20 of 105

1.

Functional plasticity of the N/OFQ-NOP receptor system determines analgesic properties of NOP receptor agonists.

Schröder W, Lambert DG, Ko MC, Koch T.

Br J Pharmacol. 2014 Aug;171(16):3777-800. doi: 10.1111/bph.12744. Review.

2.

Effects of spinally administered bifunctional nociceptin/orphanin FQ peptide receptor/μ-opioid receptor ligands in mouse models of neuropathic and inflammatory pain.

Sukhtankar DD, Zaveri NT, Husbands SM, Ko MC.

J Pharmacol Exp Ther. 2013 Jul;346(1):11-22. doi: 10.1124/jpet.113.203984. Epub 2013 May 7.

3.

Cebranopadol: a novel potent analgesic nociceptin/orphanin FQ peptide and opioid receptor agonist.

Linz K, Christoph T, Tzschentke TM, Koch T, Schiene K, Gautrois M, Schröder W, Kögel BY, Beier H, Englberger W, Schunk S, De Vry J, Jahnel U, Frosch S.

J Pharmacol Exp Ther. 2014 Jun;349(3):535-48. doi: 10.1124/jpet.114.213694. Epub 2014 Apr 8.

4.

Nociceptin/orphanin FQ receptor activation attenuates antinociception induced by mixed nociceptin/orphanin FQ/mu-opioid receptor agonists.

Khroyan TV, Polgar WE, Jiang F, Zaveri NT, Toll L.

J Pharmacol Exp Ther. 2009 Dec;331(3):946-53. doi: 10.1124/jpet.109.156711. Epub 2009 Aug 27.

5.

Endogenous nociceptin/orphanin FQ signalling produces opposite spinal antinociceptive and supraspinal pronociceptive effects in the mouse formalin test: pharmacological and genetic evidences.

Rizzi A, Nazzaro C, Marzola GG, Zucchini S, Trapella C, Guerrini R, Zeilhofer HU, Regoli D, Calo' G.

Pain. 2006 Sep;124(1-2):100-8. Epub 2006 May 11.

PMID:
16697109
6.

The therapeutic potential of nociceptin/orphanin FQ receptor agonists as analgesics without abuse liability.

Lin AP, Ko MC.

ACS Chem Neurosci. 2013 Feb 20;4(2):214-24. doi: 10.1021/cn300124f. Epub 2012 Nov 6. Review.

7.

Designing bifunctional NOP receptor-mu opioid receptor ligands from NOP-receptor selective scaffolds. Part II.

Journigan VB, Polgar WE, Khroyan TV, Zaveri NT.

Bioorg Med Chem. 2014 Apr 15;22(8):2508-16. doi: 10.1016/j.bmc.2014.02.047. Epub 2014 Mar 5.

8.

Roles of μ-opioid receptors and nociceptin/orphanin FQ peptide receptors in buprenorphine-induced physiological responses in primates.

Cremeans CM, Gruley E, Kyle DJ, Ko MC.

J Pharmacol Exp Ther. 2012 Oct;343(1):72-81. doi: 10.1124/jpet.112.194308. Epub 2012 Jun 28.

9.

Nociceptin/orphanin FQ receptor and pain: Feasibility of the fourth opioid family member.

Di Cesare Mannelli L, Micheli L, Ghelardini C.

Eur J Pharmacol. 2015 Nov 5;766:151-4. doi: 10.1016/j.ejphar.2015.08.012. Epub 2015 Aug 13.

PMID:
26277324
10.

[Dmt1]N/OFQ(1-13)-NH2: a potent nociceptin/orphanin FQ and opioid receptor universal agonist.

Molinari S, Camarda V, Rizzi A, Marzola G, Salvadori S, Marzola E, Molinari P, McDonald J, Ko MC, Lambert DG, Calo' G, Guerrini R.

Br J Pharmacol. 2013 Jan;168(1):151-62. doi: 10.1111/j.1476-5381.2012.02115.x.

11.

Differential effects of nociceptin/orphanin FQ (NOP) receptor agonists in acute versus chronic pain: studies with bifunctional NOP/μ receptor agonists in the sciatic nerve ligation chronic pain model in mice.

Khroyan TV, Polgar WE, Orduna J, Montenegro J, Jiang F, Zaveri NT, Toll L.

J Pharmacol Exp Ther. 2011 Nov;339(2):687-93. doi: 10.1124/jpet.111.184663. Epub 2011 Aug 22.

13.

Quantitative study of [Tyr10]nociceptin/orphanin FQ (1-11) at NOP receptors in rat periaqueductal gray and expressed NOP receptors in HEK293 cells.

Liao YY, Lee CW, Ho IK, Chiou LC.

Life Sci. 2012 Feb 13;90(7-8):306-12. doi: 10.1016/j.lfs.2011.12.004. Epub 2011 Dec 22.

PMID:
22213115
14.

Differential effects of opioid-related ligands and NSAIDs in nonhuman primate models of acute and inflammatory pain.

Sukhtankar DD, Lee H, Rice KC, Ko MC.

Psychopharmacology (Berl). 2014 Apr;231(7):1377-87. doi: 10.1007/s00213-013-3341-0. Epub 2013 Nov 12.

15.

The biology of Nociceptin/Orphanin FQ (N/OFQ) related to obesity, stress, anxiety, mood, and drug dependence.

Witkin JM, Statnick MA, Rorick-Kehn LM, Pintar JE, Ansonoff M, Chen Y, Tucker RC, Ciccocioppo R.

Pharmacol Ther. 2014 Mar;141(3):283-99. doi: 10.1016/j.pharmthera.2013.10.011. Epub 2013 Nov 1. Review. Erratum in: Pharmacol Ther. 2014 Sep;143(3):351.

PMID:
24189487
16.

Antinociceptive effects of spinally administered nociceptin/orphanin FQ and its N-terminal fragments on capsaicin-induced nociception.

Katsuyama S, Mizoguchi H, Komatsu T, Sakurada C, Tsuzuki M, Sakurada S, Sakurada T.

Peptides. 2011 Jul;32(7):1530-5. doi: 10.1016/j.peptides.2011.05.028. Epub 2011 Jun 6.

PMID:
21672568
17.

Pharmacogenomic study of the role of the nociceptin/orphanin FQ receptor and opioid receptors in diabetic hyperalgesia.

Rutten K, Tzschentke TM, Koch T, Schiene K, Christoph T.

Eur J Pharmacol. 2014 Oct 15;741:264-71. doi: 10.1016/j.ejphar.2014.08.011. Epub 2014 Aug 26.

PMID:
25169429
18.

Antinociceptive effects of nociceptin/orphanin FQ administered intrathecally in monkeys.

Ko MC, Naughton NN.

J Pain. 2009 May;10(5):509-16. doi: 10.1016/j.jpain.2008.11.006. Epub 2009 Feb 23.

19.

Nociceptin/orphanin FQ and its receptor--potential targets for pain therapy?

Zeilhofer HU, Calò G.

J Pharmacol Exp Ther. 2003 Aug;306(2):423-9. Epub 2003 Apr 29.

20.

Orphanin FQ inhibits capsaicin-induced thermal nociception in monkeys by activation of peripheral ORL1 receptors.

Ko MC, Naughton NN, Traynor JR, Song MS, Woods JH, Rice KC, McKnight AT.

Br J Pharmacol. 2002 Feb;135(4):943-50.

Format
Items per page
Sort by

Send to:

Choose Destination

Supplemental Content

Write to the Help Desk